Zur Zeit liegt uns keine Inhaltsangabe vor.
Inhaltsverzeichnis
One: Pathophysiology. - 1. Role of cell culture in the management of haematological diseases. - 2. Oxygen transport to the tissue and blood viscosity. - 3. Infection prevention in neutropenic patients. - 4. Apheresis units: designs and future applications. - 5. Platelets for transfusion: collection, storage and clinical efficacy. - 6. Leukapheresis: clinical experience and post-transfusion control. - 7. Plasma proteins for therapeutic use: past, present and future. - 8. Clinical significance of tissue antigens. - 9. Clinical significance of red cell blood groups. - 10. The crossmatch: how much is enough? . - 11. Isoimmunisation in pregnancy: diagnosis, treatment and prevention. - 12. Immune plasma for immunoglobulin. - Two: Clinical Practice. - 1. Blood and blood components: uses and abuses. - 2. Massive transfusion and its effects in clinical practice. - 3. Diagnosis of bleeding disorders. - 4. Treatment of the haemophilias. - 5. Advances in the treatment of thrombocytopenia. - 6. Red cell therapy. - 7. Blood transfusion in sickle cell disease. - 8. Supportive care in leukemia treatment. - 9. Immunosuppression and oncology. - 10. Use of immunoglobulins. - 11. Bone marrow transplantation (BMT). - 12. Transfusion support and obstetrical haemorrhage. - 13. Cardiac operations and transfusion requirements. - 14. Supportive therapy for liver transplantation. - 15. Supportive therapy in the new born. - 16. Therapeutic plasma exchange. - 17. Transfusion related morbidity and mortality in the intensive care facility. - 18. Infections transmitted by blood transfusion. - Three: Future Trends. - 1. Hepatitis B in pregnancy. - 2. Interferons: past, present and future. - 3. The use of antibody in the malignant blood diseases. - 4. Therapeutic approaches to abnormalities of blood rheology in vascular disease. - 5. Can wesupport comprehensive home care for haemophiliacs? . - 6. Transfusion support in a community disaster. - 7. Comprehensive haemotherapy program for developing countries. - 8. Artificial blood substitutes.